Thelansis

  The U.S. Food and Drug Administration (FDA) has granted fast-track designation to FELIQS’ lead product, FLQ-101, which aims to prevent retinopathy of prematurity (ROP). FLQ-101 can be administered orally or intravenously once daily and is designed to enhance the physiological response of vascularization in the retina, offering protection against inflammation and abnormal neovascularization. In the first quarter of 2025, FELIQS will commence the Phase Ib/II tROPhy-1 study in the US and Japan. Publish Date: 04-11-2024   Source: Feliqs Corporation Retinopathy of prematurity (ROP) is an eye disease that affects some premature babies born before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a condition that affects the retina, the tissue at the back of the eye. The retina detects light and sends signals to the brain, allowing you to see. Unwanted blood vessels grow on the baby’s retina due to ROP. These blood vessels can later cause serious eye and vi...

  Retinopathy of prematurity (ROP) is an eye disease that affects some premature babies born before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a condition that affects the retina, the tissue at the back of the eye. The retina detects light and sends signals to the brain, allowing you to see. Unwanted blood vessels grow on the baby's retina due to ROP. These blood vessels can later cause serious eye and vision problems. Sometimes immediate treatment is required to avoid blindness. If not treated promptly, the child may suffer from severe permanent vision loss or even go blind. Most babies with ROP normally see for their age. Vision is only threatened when ROP progresses to the most severe stages. Fortunately, the majority of ROP resolves without causing vision loss. The most important factors in preventing ROP-related vision loss are effective screening and timely treatment (when indicated. Birth weight and gestational age are the most critical risk factors ...

 Retinopathy of prematurity (ROP) is an eye disease that affects some premature babies born before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a condition that affects the retina, the tissue at the back of the eye. The retina detects light and sends signals to the brain, allowing you to see. Unwanted blood vessels grow on the baby's retina due to ROP. These blood vessels can later cause serious eye and vision problems. Sometimes immediate treatment is required to avoid blindness. If not treated promptly, the child may suffer from severe permanent vision loss or even go blind. Most babies with ROP normally see for their age. Vision is only threatened when ROP progresses to the most severe stages. Fortunately, the majority of ROP resolves without causing vision loss. The most important factors in preventing ROP-related vision loss are effective screening and timely treatment (when indicated. Birth weight and gestational age are the most critical risk factors for...